尊敬的Chrome用户,由于旧版本与本站存在兼容问题,如访问崩溃,请使用Firefox或IE访问,亦可更新最新版Chrome。
客服邮箱:info@sznaber.com
深圳南北医药有限公司
SHENZHEN NABER MEDICINE CO., LTD

深圳市南北医药有限公司成立于1987年,在医药行业发展已有三十余载,主要业务涉及药品、医疗器械代理、专业配送、批发分销和药店连锁经营等;我司被广东省食品药品监督管理局批准为深圳市麻醉药品、第一类精神药品的经营企业之一(全深圳市仅有两家企业具有该类药品的经营资质)。


经过历年来的辛勤努力,我司在原有的基础上不断发展壮大,先后在深圳全资注册成立了深圳市南北药行连锁有限公司、深圳市利物蒲医疗器械有限公司,南北药行全资收购深圳市宝华药行连锁有限公司、深圳市健华药行连锁有限公司,并在广州、东莞、惠州、江门和粤西等地区均设有分、子公司及办事处,下属分店有1005家,主要分布在深圳市、广州市、东莞市、惠州市、江门市和粤西地区等;其中深圳市零售药店633家(福田区51家;罗湖区41家;盐田区20家,南山区53家;宝安区187家;龙华新区112家;龙岗区101家;公明新区46家;坪山新区22家);现有员工5000多人,内设行政人力资源部、财务部、质管部、商采部、医疗机构事业部、营运部、新药部、处方药(医院)营运部、器械部、中药部、信息部、配送中心等12个职能部门。到2018年止,公司及其子公司分别获得“全国医药商业企业100强”和“全国药品连锁零售50强”、深圳市“信誉好商店”、“深圳市连锁经营20强企业”和“中国药店连锁行业十大竞争力品牌”等殊荣。家喻户晓、历史悠长的品牌,成熟稳定的经营班子,规模化的门店数量,优质的服务、产品质量,与时俱进的公司战略都是我司极具优势的核心竞争力。


2017年,我司总销售额18.3亿元,其中总部销售额8.3亿元,分店销售额为10亿元;2018年,我司总销售额19.8亿元,其中总部销售额8.8亿元,分店销售额为11亿元。2019年实现销售额22亿元。为加快公司的发展速度,公司已引入中信建投对公司进行首轮战略投资;今年深创投、高瓴资本、恒大人寿、招商资本等六大投行也计划进行B轮投资。计划未来五年引入资本市场投资总额20亿元,在国家十三五“健康中国”的 宏伟战略指引下,面对大健康、大医疗、新一代互联网的市场环境,我司将通过引入战略资本和转变传统的经营模式,全力发展药品连锁零售业,并突破传统的药店经营理念和方式,引入新一代互联网和人工智能平台,打造具有南北特色的 “智能药店”和“智慧社区家庭健康服务平台”,并计划到2022年在全省乃至全国设立分公司十家,新增零售连锁药店3500家,实现零售规模达70亿元。届时在国内A股主板或香港主板市。

 

 

 

深圳市南北医药有限公司

2020217



SHENZHEN NABER MEDICINE CO.,LTD,founded in 1987, has developed in the pharmaceutical industry for more than 30 years,and our main business involves pharmaceuticals, medical device agents, professional distribution, wholesale distribution, and pharmacy chain operations.Our company has been allowed by Guangdong Food and Drug Administration to manage narcotic drugs and first-class psychoactive drugs which just only two companies in Shenzhen have the qualifications to manage such drugs.


        After years of hard work, our company has continued to grow and develop on the original basis, we has registered SHENZHEN NABER PHARMACY CHAIN CO.,LTD, SHENZHEN LIWUPU MEDICAL DEVICES CO.,LTD,acquired SHENZHEN BAOHUA PHARMACY CHAIN CO.,LTD and SHENZHEN JIANHUA PHARMACY CHAIN CO.,LTD....and set up branches, subsidiaries and offices in cities such as Guangzhou, Dongguan, Huizhou, Jiangmen and the west Guangdong, with 1005 affiliated branches Stores, mainly distributed in Shenzhen, Guangzhou, Dongguan, Huizhou, Jiangmen, and wester the Guangdong; among them, there are 633 retail pharmacies in Shenzhen (51 in Futian District; 41 in Luohu District; 20 in Yantian District, Nanshan District) 53; Baoan District 187; Longhua  District 112; Longgang District 101; Gongming District 46; Pingshan District 22); Existing staff of more than 5,000 people, twelve functional departments including administrative&human resources department, finance department, quality control department,commercial Procurement department,medical institution department,chain operation department, new drug department, prescription drug (hospital) operation department, medical device department, traditional Chinese medicine department,information department,and distribution center. As of 2018, the company and its subsidiaries were awarded the "Top 100 Pharmaceutical Commercial Enterprises in China" and "Top 50 National Drug Chain Retailers", "Reputable Stores in Shenzhen", "Top 20 Chain Stores in Shenzhen" and "China Top ten competitive brands in the pharmacy chain industry" and other awards. A well-known and long-established brand, a mature and stable business team, a large number of stores, high-quality services, product quality, and the strategy of advancing with the times,are all core advantages of our company.


         In 2017, our company's total sales were 1.83 billion yuan, of which headquarters sales were 830 million yuan and branch sales were 1 billion yuan; in 2018, our company's total sales were 1.98 billion yuan, of which headquarters sales were 880 million yuan and branch sales is 1.1 billion yuan. In 2019, it achieved sales of 2.2 billion yuan. In order to speed up the company's development, the company has introduced CITIC Construction Investment to make the first round of strategic investment in the company; this year, six major investment banks such as Shenzhen Venture Capital, Gaoyuan Capital, Evergrande Life Insurance, and China Merchants Capital plan to make B-round investments. We are planned to introduce about a total 2 billion yuan from capital market in the next five years. Under the guidance of the national 13th Five-Year policy forHealthy of China, in the face of the marketing environment of great health, great medical care, and new generation of Internet, our company will introduce strategic capital and change the traditional business model, fully develop the industry of pharmaceutical chain retail , and break through the traditional philosophy and methods of pharmacy business , introduce a new generation of Internet and artificial intelligence platforms, create a "smart pharmacy" and "smart community family health service platform" with our own type. We plan to set up 10 branches in the whole province and even the whole country by 2022, add 3,500 retail chain pharmacies, and achieve a retail scale of 7 billion yuan.At that time,we will be listed on share stock A market or Hong Kong share stock market.